Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening

Journal of Experimental Medicine

Volumn 209, Issue 7, 2012, Pages 1273-1287

  DiGiandomenico, Antonio ^a   Warrener, Paul ^a   Hamilton, Melissa ^a   Guillard, Sandrine ^a   Ravn, Peter ^a   Minter, Ralph ^a   Camara, Maria Margarita ^a   Venkatraman, Vignesh ^a   MacGill, Randall S ^a   Lin, Jia ^a   Wang, Qun ^a   Keller, Ashley Elaine ^a   Bonnell, Jessica C ^a   Tomich, Mladen ^a   Jermutus, Lutz ^a   McCarthy, Michael P ^a   Melnick, David A ^b   Suzich, JoAnn A ^a   Stover, C Kendall ^a  

^a MEDIMMUNE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; EXOPOLYSACCHAIRDE PSL; EXOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAM 003; MONOCLONAL ANTIBODY CAM 004; MONOCLONAL ANTIBODY CAM 005; MONOCLONAL ANTIBODY R347; MONOCLONAL ANTIBODY WAPR 001; MONOCLONAL ANTIBODY WAPR 002; MONOCLONAL ANTIBODY WAPR 003; MONOCLONAL ANTIBODY WAPR 016; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL CELL; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BINDING AFFINITY; BIOFILM; CELL ADHESION; CELL KILLING; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EPITOPE MAPPING; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; LUNG INFECTION; MAMMAL CELL; MOUSE; NONHUMAN; OPSONOPHAGOCYTOSIS; PHAGE DISPLAY; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SCREENING; SEROTYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL ADHESION; CELL LINE, TUMOR; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICROBIAL VIABILITY; MUTATION; PEPTIDE LIBRARY; PNEUMONIA; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEROTYPING; SINGLE-CHAIN ANTIBODIES;

EID: 84864291211     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20120033     Document Type: Article

References (59)

1. Beerli, R.R., M. Bauer, R.B. Buser, M. Gwerder, S. Muntwiler, P. Maurer, P. Saudan, and M.F. Bachmann. 2008. Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl. Acad. Sci. USA. 105:14336-14341. http://dx.doi.org/10.1073/pnas.0805942105
2. Borlee, B.R., A.D. Goldman, K. Murakami, R. Samudrala, D.J. Wozniak, and M.R. Parsek. 2010. Pseudomonas aeruginosa uses a cyclic-di-GMPregulated adhesin to reinforce the biofilm extracellular matrix. Mol. Microbiol. 75:827-842. http://dx.doi.org/10.1111/j.1365-2958.2009.06991.x
3. Buchwald, U.K., and L. Pirofski. 2003. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:945-968. http://dx.doi.org/10.2174/1381612033455189
4. Burns, J.L., R.L. Gibson, S. McNamara, D. Yim, J. Emerson, M. Rosenfeld, P. Hiatt, K. McCoy, R. Castile, A.L. Smith, and B.W. Ramsey. 2001. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183:444-452. http://dx.doi.org/10.1086/318075
5. Byrd, M.S., I. Sadovskaya, E. Vinogradov, H. Lu, A.B. Sprinkle, S.H. Richardson, L. Ma, B. Ralston, M.R. Parsek, E.M. Anderson, et al. 2009. Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. Mol. Microbiol. 73:622-638. http://dx.doi.org/10.1111/j.1365-2958.2009.06795.x
6. Byrd, M.S., B. Pang, W. Hong, E.A. Waligora, R.A. Juneau, C.E. Armbruster, K.E. Weimer, K. Murrah, E.E. Mann, H. Lu, et al. 2011. Direct evaluation of Pseudomonas aeruginosa biofilm mediators in a chronic infection model. Infect. Immun. 79:3087-3095. http://dx.doi.org/10.1128/IAI.00057-11
7. Campisano, A., C. Schroeder, M. Schemionek, J. Overhage, and B.H. Rehm. 2006. PslD is a secreted protein required for biofilm formation by Pseudomonas aeruginosa. Appl. Environ. Microbiol. 72:3066-3068. http://dx.doi.org/10.1128/AEM.72.4.3066-3068.2006
8. Casadevall, A., and M.D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38:1695-1702.
9. Casadevall, A., and M.D. Scharff. 1995. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21:150-161. http://dx.doi.org/10.1093/clinids/21.1.150
10. Choi, K.H., J.B. Gaynor, K.G. White, C. Lopez, C.M. Bosio, R.R. Karkhoff-Schweizer, and H.P. Schweizer. 2005. A Tn7-based broad-range bacterial cloning and expression system. Nat. Methods. 2:443-448. http://dx.doi.org/10.1038/nmeth765
11. Colvin, K.M., V.D. Gordon, K. Murakami, B.R. Borlee, D.J. Wozniak, G.C. Wong, and M.R. Parsek. 2011. The pel polysaccharide can serve a structural and protective role in the biofilm matrix of Pseudomonas aeruginosa. PLoS Pathog. 7:e1001264. http://dx.doi.org/10.1371/journal.ppat.1001264
12. DiGiandomenico, A., J. Rao, and J.B. Goldberg. 2004. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect. Immun. 72:7012-7021. http://dx.doi.org/10.1128/IAI.72.12.7012-7021.2004
13. DiGiandomenico, A., J. Rao, K. Harcher, T.S. Zaidi, J. Gardner, A.N. Neely, G.B. Pier, and J.B. Goldberg. 2007. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. Natl. Acad. Sci. USA. 104:4624-4629. http://dx.doi.org/10.1073/pnas.0608657104
14. Döring, G., C. Pfeiffer, U. Weber, A. Mohr-Pennert, and F. Dorner. 1995. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am. J. Respir. Crit. Care Med. 151:983-985.
15. Döring, G., C. Meisner, and M. Stern; for the Flagella Vaccine Trial Study Group. 2007. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. USA. 104:11020-11025. http://dx.doi.org/10.1073/pnas.0702403104
16. Fernandes, P. 2006. Antibacterial discovery and development-the failure of success? Nat. Biotechnol. 24:1497-1503. http://dx.doi.org/10.1038/nbt1206-1497
17. Franklin, M.J., D.E. Nivens, J.T. Weadge, and P.L. Howell. 2011. Biosynthesis of the Pseudomonas aeruginosa Extracellular Polysaccharides, Alginate, Pel, and Psl. Front Microbiol. 2:167.
18. Friedman, L., and R. Kolter. 2004. Genes involved in matrix formation in Pseudomonas aeruginosa PA14 biofilms. Mol. Microbiol. 51:675-690. http://dx.doi.org/10.1046/j.1365-2958.2003.03877.x
19. Fukuchi, K., S.C. Steiniger, E. Deryugina, Y. Liu, C.A. Lowery, C. Gloeckner, B. Zhou, G.F. Kaufmann, J.P. Quigley, and K.D. Janda. 2010. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1. Mol. Pharm. 7:245-253. http://dx.doi.org/10.1021/mp900236t
20. Ghafoor, A., I.D. Hay, and B.H. Rehm. 2011. Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture. Appl. Environ. Microbiol. 77:5238-5246. http://dx.doi.org/10.1128/AEM.00637-11
21. Hancock, R.E., L.M. Mutharia, L. Chan, R.P. Darveau, D.P. Speert, and G.B. Pier. 1983. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect. Immun. 42:170-177.
22. Hoang, T.T., R.R. Karkhoff-Schweizer, A.J. Kutchma, and H.P. Schweizer. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene. 212:77-86. http://dx.doi.org/10.1016/S0378-1119(98)00130-9
23. Hogardt, M., and J. Heesemann. 2010. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300:557-562. http://dx.doi.org/10.1016/j.ijmm.2010.08.008
24. Irie, Y., M. Starkey, A.N. Edwards, D.J. Wozniak, T. Romeo, and M.R. Parsek. 2010. Pseudomonas aeruginosa biofilm matrix polysaccharide Psl is regulated transcriptionally by RpoS and post-transcriptionally by RsmA. Mol. Microbiol. 78:158-172.
25. Jackson, K.D., M. Starkey, S. Kremer, M.R. Parsek, and D.J. Wozniak. 2004. Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J. Bacteriol. 186:4466-4475. http://dx.doi.org/10.1128/JB.186.14.4466-4475.2004
26. Jovcic, B., Z. Lepsanovic, V. Suljagic, G. Rackov, J. Begovic, L. Topisirovic, and M. Kojic. 2011. Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob. Agents Chemother. 55:3929-3931. http://dx.doi.org/10.1128/AAC.00226-11
27. Kocharova, N.A., Y.A. Knirel, A.S. Shashkov, N.K. Kochetkov, and G.B. Pier. 1988. Structure of an extracellular cross-reactive polysaccharide from Pseudomonas aeruginosa immunotype 4. J. Biol. Chem. 263:11291-11295.
28. Kunz, A.N., and I. Brook. 2010. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy. 56:492-500. http://dx.doi.org/10.1159/000321018
29. Lange, R.P., H.H. Locher, P.C. Wyss, and R.L. Then. 2007. The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Des. 13:3140-3154. http://dx.doi.org/10.2174/138161207782110408
30. Lloyd, C., D. Lowe, B. Edwards, F. Welsh, T. Dilks, C. Hardman, and T. Vaughan. 2009. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng. Des. Sel. 22:159-168. http://dx.doi.org/10.1093/protein/gzn058
31. Ma, L., M. Conover, H. Lu, M.R. Parsek, K. Bayles, and D.J. Wozniak. 2009. Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog. 5:e1000354. http://dx.doi.org/10.1371/journal.ppat.1000354
32. Ma, L., S. Wang, D. Wang, M.R. Parsek, and D.J. Wozniak. 2012. The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms. FEMS Immunol. Med. Microbiol.
33. Martin, D.W., M.J. Schurr, M.H. Mudd, J.R. Govan, B.W. Holloway, and V. Deretic. 1993. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc. Natl. Acad. Sci. USA. 90:8377-8381. http://dx.doi.org/10.1073/pnas.90.18.8377
34. Matsukawa, M., and E.P. Greenberg. 2004. Putative exopolysaccharide synthesis genes influence Pseudomonas aeruginosa biofilm development. J. Bacteriol. 186:4449-4456. http://dx.doi.org/10.1128/JB.186.14.4449-4456.2004
35. Mishra, M., M.S. Byrd, S. Sergeant, A.K. Azad, M.R. Parsek, L. McPhail, L.S. Schlesinger, and D.J. Wozniak. 2012. Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell. Microbiol. 14:95-106. http://dx.doi.org/10.1111/j.1462-5822.2011.01704.x
36. Moscoso, J.A., H. Mikkelsen, S. Heeb, P. Williams, and A. Filloux. 2011. The Pseudomonas aeruginosa sensor RetS switches type III and type VI secretion via c-di-GMP signalling. Environ. Microbiol. 13:3128-3138. http://dx.doi.org/10.1111/j.1462-2920.2011.02595.x
37. Neely, A.N., I.A. Holder, J.P. Wiener-Kronish, and T. Sawa. 2005. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns. 31:153-158. http://dx.doi.org/10.1016/j.burns.2004.09.002
38. Oganesyan, V., C. Gao, L. Shirinian, H. Wu, and W.F. Dall'Acqua. 2008. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr. 64:700-704. http://dx.doi.org/10.1107/S0907444908007877
39. Overhage, J., M. Schemionek, J.S. Webb, and B.H. Rehm. 2005. Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formation. Appl. Environ. Microbiol. 71:4407-4413. http://dx.doi.org/10.1128/AEM.71.8.4407-4413.2005
40. Payne, D.J., M.N. Gwynn, D.J. Holmes, and D.L. Pompliano. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. http://dx.doi.org/10.1038/nrd2201
41. Persic, L., A. Roberts, J. Wilton, A. Cattaneo, A. Bradbury, and H.R. Hoogenboom. 1997. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene. 187:9-18. http://dx.doi.org/10.1016/S0378-1119(96)00628-2
42. Pier, G.B., and R.B. Markham. 1986. Serotypes and immune responses to Pseudomonas aeruginosa. In Manual of Clinical Laboratory Immunology. N.R. Rose, H. Friedman, and J.L. Fahey, editors. American Society of Microbiology, Washington, DC. Page 92.
43. Pier, G.B., D. Boyer, M. Preston, F.T. Coleman, N. Llosa, S. Mueschenborn-Koglin, C. Theilacker, H. Goldenberg, J. Uchin, G.P. Priebe, et al. 2004. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J. Immunol. 173:5671-5678.
44. Pollack, M., and L.S. Young. 1979. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J. Clin. Invest. 63:276-286. http://dx.doi.org/10.1172/JCI109300
45. Reiche, N., A. Jung, T. Brabletz, T. Vater, T. Kirchner, and G. Faller. 2002. Generation and characterization of human monoclonal scFv antibodies against Helicobacter pylori antigens. Infect. Immun. 70:4158-4164. http://dx.doi.org/10.1128/IAI.70.8.4158-4164.2002
46. Ryder, C., M. Byrd, and D.J. Wozniak. 2007. Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr. Opin. Microbiol. 10:644-648. http://dx.doi.org/10.1016/j.mib.2007.09.010
47. Sato, H., D.W. Frank, C.J. Hillard, J.B. Feix, R.R. Pankhaniya, K. Moriyama, V. Finck-Barbançon, A. Buchaklian, M. Lei, R.M. Long, et al. 2003. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J. 22:2959-2969. http://dx.doi.org/10.1093/emboj/cdg290
48. Sato, H., M.L. Hunt, J.J. Weiner, A.T. Hansen, and D.W. Frank. 2011. Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa. PLoS ONE. 6:e18356. http://dx.doi.org/10.1371/journal.pone.0018356
49. Sawa, T., T.L. Yahr, M. Ohara, K. Kurahashi, M.A. Gropper, J.P. Wiener-Kronish, and D.W. Frank. 1999. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat. Med. 5:392-398. http://dx.doi.org/10.1038/7391
50. Saylor, C., E. Dadachova, and A. Casadevall. 2009. Monoclonal antibodybased therapies for microbial diseases. Vaccine. 27(Suppl 6):G38-G46. http://dx.doi.org/10.1016/j.vaccine.2009.09.105
51. Schweizer, H.P. 1992. Allelic exchange in Pseudomonas aeruginosa using novel ColE1-type vectors and a family of cassettes containing a portable oriT and the counter-selectable Bacillus subtilis sacB marker. Mol. Microbiol. 6:1195-1204. http://dx.doi.org/10.1111/j.1365-2958.1992.tb01558.x
52. Schweizer, H.D. 1993. Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis. Biotechniques. 15:831-834.
53. Stover, C.K., X.Q. Pham, A.L. Erwin, S.D. Mizoguchi, P. Warrener, M.J. Hickey, F.S. Brinkman, W.O. Hufnagle, D.J. Kowalik, M. Lagrou, et al. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 406:959-964. http://dx.doi.org/10.1038/35023079
54. Ulbrandt, N.D., H. Ji, N.K. Patel, J.M. Riggs, Y.A. Brewah, S. Ready, N.E. Donacki, K. Folliot, A.S. Barnes, K. Senthil, et al. 2006. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J. Virol. 80:7799-7806. http://dx.doi.org/10.1128/JVI.00318-06
55. Underhill, D.M., and A. Ozinsky. 2002. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20:825-852. http://dx.doi.org/10.1146/annurev.immunol.20.103001.114744
56. Vaughan, T.J., A.J. Williams, K. Pritchard, J.K. Osbourn, A.R. Pope, J.C. Earnshaw, J. McCafferty, R.A. Hodits, J. Wilton, and K.S. Johnson. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14:309-314. http://dx.doi.org/10.1038/nbt0396-309
57. Wrammert, J., K. Smith, J. Miller, W.A. Langley, K. Kokko, C. Larsen, N.Y. Zheng, I. Mays, L. Garman, C. Helms, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 453:667-671. http://dx.doi.org/10.1038/nature06890
58. Yang, L., W. Hengzhuang, H. Wu, S. Damkiaer, N. Jochumsen, Z. Song, M. Givskov, N. Høiby, and S. Molin. 2012. Polysaccharides serve as scaffold of biofilms formed by mucoid Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol.
59. Zou, N., T. Newsome, B. Li, S. Tsai, and S.C. Lo. 2007. Human singlechain Fv antibodies against Burkholderia mallei and Burkholderia pseudomallei. Exp. Biol. Med. (Maywood). 232:550-556.